Skip to content

Clinical study on the ERAS Concept-based Oliceridine Cocktail Combined with Adductor Canal Block for Multimodal Analgesia in TKA

Clinical study on the ERAS Concept-based Oliceridine Cocktail Combined with Adductor Canal Block for Multimodal Analgesia in TKA

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500114367
Enrollment
Unknown
Registered
2025-12-11
Start date
2024-08-15
Completion date
Unknown
Last updated
2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative

Interventions

control group:The control group received a 20ml adductor canal block under ultrasound guidance with 0.4% ropivacaine after surgery
Experimental Group:The experimental group was administered the 'cocktail' formula + 0.4% ropivacaine 20 ml for muscle relaxation and block under ultrasound guidance.

Sponsors

Ordos Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 80 Years

Inclusion criteria

Inclusion criteria: Stage IV knee osteoarthritis, first-time total knee arthroplasty;The American Society of Anesthesiologists (ASA) physical status classification was I–II; age >=60 years; without severe dysfunction of major organs such as heart, lung, liver, or kidney; patients who voluntarily participated in the study with informed consent.

Exclusion criteria

Exclusion criteria: Patients undergoing bilateral knee replacement; those with other diseases affecting walking ability such as myasthenia gravis; patients undergoing knee revision surgery, malignant tumors, or other diseases; severe systemic diseases such as severe hypertension (crisis), severe diabetes (ketosis, acidosis), coronary heart disease, Chronic Obstructive Pulmonary Disease, asthma, respiratory failure, severe arrhythmias (e.g., atrial fibrillation), second-degree or higher atrioventricular block, sick sinus syndrome, severe valvular heart disease, heart failure, renal failure, stroke or myocardial infarction within the past 6 months, Alzheimer's disease, Parkinson's disease, etc.; patients with mental illnesses or communication disorders; those with a history of chronic pain or allergic reactions to multiple medications; individuals with a history of alcohol abuse or drug addiction; those allergic to opioid drugs; patients with abnormal coagulation function; and those who refuse or are unable to cooperate with the study.

Design outcomes

Primary

MeasureTime frame
Postoperative resting pain scores at 6, 12, 24, and 48 hours;

Secondary

MeasureTime frame
1. postoperative pain scores during activity at 6, 12, 24, and 48 hours;; 2. muscle strength assessment at 6, 12, 24, and 48 hours; ;3. preoperative and postoperative 24-hour anxiety and depression scores; ;4. postoperative nausea and vomiting incidence within 48 hours.;

Countries

China

Contacts

Public ContactJing xin

Ordos Central Hospital

xin19811226@163.com+86 150 4949 3636

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026